Insmed is trading 4.11% lower at $116.56, with no definitive cause identified.
- Shares are down despite broader U.S. indices moving modestly higher; the move appears isolated.
- No fresh negative company-specific announcement or same-direction catalyst was identified for September 25, 2026.
- Goldman Sachs initiated coverage on September 24 with a Buy rating and $188 target, which does not explain the decline.